These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
179 related items for PubMed ID: 7723403
1. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Bendall LJ, Kortlepel K, Gottlieb DJ. Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403 [Abstract] [Full Text] [Related]
2. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1. Triozzi PL, Eicher DM, Smoot J, Rinehart JJ. Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453 [Abstract] [Full Text] [Related]
3. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C, García-Pérez MJ, Ramirez R, Martín C, Alvarez MA, Martinez F, Gómez P, García-Castellano JM, Torres A. Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [Abstract] [Full Text] [Related]
5. Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors. Carlo-Stella C, Mangoni L, Almici C, Frassoni F, Fiers W, Rizzoli V. Leukemia; 1990 Aug; 4(8):561-6. PubMed ID: 1697011 [Abstract] [Full Text] [Related]
6. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. Galandrini R, Albi N, Zarcone D, Grossi CE, Velardi A. Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184 [Abstract] [Full Text] [Related]
7. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity. Azuma A, Yagita H, Matsuda H, Okumura K, Niitani H. Cancer Res; 1992 Sep 15; 52(18):4890-4. PubMed ID: 1381273 [Abstract] [Full Text] [Related]
8. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD. Immunology; 1992 Jun 15; 76(2):286-91. PubMed ID: 1353063 [Abstract] [Full Text] [Related]
9. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression. Watanabe T, Dave B, Heimann DG, Lethaby E, Kessinger A, Talmadge JE. Bone Marrow Transplant; 1997 Jun 15; 19(12):1175-81. PubMed ID: 9208110 [Abstract] [Full Text] [Related]
10. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells. Fujiwara T, Loudon WG, Grimm EA. Lymphokine Cytokine Res; 1993 Feb 15; 12(1):45-8. PubMed ID: 8096153 [Abstract] [Full Text] [Related]
11. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM. Clin Cancer Res; 1996 Feb 15; 2(2):319-30. PubMed ID: 9816175 [Abstract] [Full Text] [Related]
12. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance. Archimbaud E, Thomas X, Campos L, Fiere D, Doré JF. Leuk Res; 1992 Feb 15; 16(6-7):673-80. PubMed ID: 1378919 [Abstract] [Full Text] [Related]
13. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, Prentice HG, Hazlehurst G, Hoffbrand AV. Blood; 1991 May 01; 77(9):1996-2001. PubMed ID: 1708296 [Abstract] [Full Text] [Related]
14. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P. Leukemia; 1993 Aug 01; 7(8):1191-8. PubMed ID: 7688839 [Abstract] [Full Text] [Related]
15. Membrane-associated lymphotoxin-expressing lymphokine-activated killer cells up-regulate intercellular adhesion molecule-1 expression on target tumor cells in vitro. Kimura K, Abe Y, Horiuchi A, Miyake M, Kimura S. Cell Immunol; 1995 Aug 01; 164(1):119-25. PubMed ID: 7634343 [Abstract] [Full Text] [Related]
16. Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cytolysis: evidence for additional ligands for effector cell beta integrins. Akella R, Hall RE. Eur J Immunol; 1992 Apr 01; 22(4):1069-74. PubMed ID: 1348028 [Abstract] [Full Text] [Related]
17. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro. Braun S, Gerhartz HH, Schmetzer HM. Haematologia (Budap); 2000 Apr 01; 30(4):271-88. PubMed ID: 11204027 [Abstract] [Full Text] [Related]
18. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells. Teichmann JV, Ludwig WD, Thiel E. Int J Hematol; 1992 Jun 01; 55(3):255-64. PubMed ID: 1498316 [Abstract] [Full Text] [Related]
19. Upregulation of HLA class II, but not intercellular adhesion molecule 1 (ICAM-1) by granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-3 (IL-3) in synergy with dexamethasone. Sadeghi R, Feldmann M, Hawrylowicz C. Eur Cytokine Netw; 1992 Jun 01; 3(4):373-80. PubMed ID: 1358241 [Abstract] [Full Text] [Related]
20. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor. Blanchard DK, Serbousek D, Djeu JY. Cancer Res; 1989 Sep 15; 49(18):5037-43. PubMed ID: 2670200 [Abstract] [Full Text] [Related] Page: [Next] [New Search]